<DOC>
	<DOC>NCT01897987</DOC>
	<brief_summary>This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT01297205 ) will be followed-up until 60 months of corrected age.</brief_summary>
	<brief_title>Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial</brief_title>
	<detailed_description>Subjects who completed the initial stage of the Phase II clinical trial will be followed-up at 7 additional visits: corrected age of 6, 12,18, 24, 36, 48, and 60 months.</detailed_description>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>Subject who completed the safety and efficacy evaluations in Pneumostem Phase II clinical trial Subject with a written consent form signed by a legal representative or a parent upon explanation of the clinical trial Subject whose parent or legal representative does not agree to participate in the study subject who is considered inappropriate to participate in the study by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>7 Months</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Human Umbilical Cord Blood Derived Mesenchymal Stem Cells</keyword>
	<keyword>Bronchopulmonary dysplasia</keyword>
	<keyword>Premature infants</keyword>
</DOC>